Siemens Healthineers Expands Production Site in Rudolstadt, Germany and Creates New Jobs

Siemens HealthineersSiemens Healthineers is expanding its site in Rudolstadt, Germany. By mid 2024, a new manufacturing building will be built on the site. The new manufacturing plant will produce electron accelerators that will be used as radiation sources for Varian's cancer therapy devices. Varian has been a Siemens Healthineers company since 2021. The hall will also expand the production line for so-called liquid metal plain bearings, a core technology of high-end computed tomography and angiography systems. The expansion of the site is expected to create around 50 new jobs by 2027. Siemens Healthineers is investing around €25 million in the 2100-square-meter manufacturing facility. The new building is to be built in a CO2-neutral manner and operated as sustainably as possible. "The expansion in Rudolstadt is a strong commitment to the location and the entire region. We want to grow here, create jobs and remain an attractive employer," says Peter Schardt, Chief Technology Officer of Siemens Healthineers and responsible for Rudolstadt as a technology location.

In order to meet the growing demand for Varian's radiotherapy equipment, the company needs a second manufacturing site for core components of its radiotherapy devices in addition to Palo Alto in the USA. In Rudolstadt, Siemens Healthineers has the necessary knowledge and already manufactures such components. The electron accelerators from Rudolstadt are to be used for the Halcyon and TrueBeam radiotherapy systems, some of which are manufactured at the Kemnath site in Germany.

Radiotherapy with so-called linear accelerators is one of the most important methods of modern cancer therapy and is used in more than half of all cancer treatments today. Linear accelerators are used both in the outpatient sector and in hospitals for the targeted treatment of cancer.

Today, around 270 employees develop and produce vacuum components, X-ray tubes and components for medical and industrial use at the Rudolstadt plant. The components are used, for example, in computed tomography, angiography systems or mammography devices. The site is also the manufacturing center for industrial electron linear accelerator systems, which are used, among others, in non-destructive material testing and scanning to check contents of shipping containers, trucks and train cars. The plant in Rudolstadt was founded in 1919.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...